Immune Effects

Why this deserves its own page

Immune modulation is not a secondary effect of Urolithin A.

It is a primary mechanism.

As evidence from the cancer-type pages accumulated, a single biological story kept emerging across NK cells, CD8-positive T cells, tumour-associated macrophages, and the tumour microenvironment.

Urolithin A appears to restore immune-cell fitness by clearing dysfunctional mitochondria, and that mitochondrial housekeeping has direct consequences for anti-tumour immune function.

That story now has human evidence behind it.

The central mechanism: mitophagy as an immune intervention

Most natural compounds discussed in oncology affect tumour cells directly.

Urolithin A does this too, but it also acts on immune cells in a way that is mechanistically distinct and increasingly well-characterised.

Immune cells — particularly CD8-positive T cells and NK cells — depend on functional mitochondria for energy production, cytokine secretion, and cytotoxic killing.

In cancer patients, and in ageing generally, mitochondrial dysfunction accumulates in immune cells.

Damaged mitochondria are not efficiently cleared.

The result is a shift toward terminally exhausted immune-cell phenotypes that cannot respond effectively to tumour antigens or to immunotherapy.

Urolithin A activates PINK1/Parkin-mediated mitophagy in immune cells.

Within hours of exposure, damaged mitochondria are tagged and selectively degraded.

This appears to trigger a downstream sequence:

• PINK1-mediated mitophagy initiates rapidly in human immune cells

• Wnt/β-catenin signalling activates downstream of mitophagy

• TCF1 expression increases, driving a stemness programme in CD8-positive T cells

• PGC-1α is upregulated, triggering compensatory mitochondrial biogenesis

• the net result is a shift away from terminal exhaustion and toward a naive-like, proliferative, functionally competent CD8-positive T-cell phenotype

This mechanism has been validated in mouse models, human cell culture, and human supplementation studies.

It is the most robustly supported immune mechanism in the current Urolithin A literature.

CD8-positive T-cell effects

Preclinical evidence

In mouse tumour models, Urolithin A treatment expanded T memory stem cells, or T-SCM cells.

These are rare, long-lived cells with superior anti-tumour cytotoxic capacity and self-renewal potential.

Critically, this T-SCM expansion was shown to suppress intestinal tumour growth in a T-cell-dependent manner.

When T cells were depleted, the anti-tumour effect of Urolithin A was substantially reduced.

That confirms that T-cell activation is not merely associated with benefit.

It is functionally required in those models.

Urolithin-A-treated mice also showed increased intratumoural CD8-positive T-cell infiltration across multiple cancer models, with cells showing a more effector-like transcriptional profile and higher granzyme B expression.

Human evidence — Nature Aging randomised trial

This is the most significant human immunology dataset for Urolithin A published to date.

A randomised, placebo-controlled trial in healthy middle-aged adults used MitoPure at 1000 mg/day for four weeks and performed comprehensive immune phenotyping.

Compared with placebo, the Urolithin A group showed:

• higher naive CD8-positive T-cell proportions

• higher Ki-67 expression on CD8-positive T cells

• lower TOX expression, which matters because TOX helps drive and maintain T-cell exhaustion

• higher TCF7 and LEF1 expression, consistent with a more stem-like programme

• higher IL7R expression, supporting survival and memory maintenance

• lower expression of several genes associated with suppression or exhaustion, including NR4A2, CREM, TGFB1, and METRNL

• greater TNF production after stimulation

• no indiscriminate increase in PD-1 expression

That last point matters because it suggests selective reversal of exhaustion programming rather than blunt global immune activation.

These findings were in healthy adults, not cancer patients.

That limit matters.

Even so, the mechanistic consistency between the mouse data, the human cell work, and this trial is strong.

Cancer-patient evidence — ASCO 2024 abstract

A prospective intervention study enrolled 25 cancer patients receiving Urolithin A supplementation.

After the study period, the reported findings included:

• expansion of total peripheral lymphocytes

• expansion of circulating NK cells

• greater mitochondrial mass in CD8-positive T cells

• a stronger naive-like CD8-positive T-cell phenotype

• more Ki-67 expression in CD8-positive T cells

• less inflammatory monocyte signatures

• lower plasma levels of several pro-inflammatory cytokines

This is conference-abstract data, not yet a full peer-reviewed publication.

The sample size is small.

Even so, it is the first prospective human cancer-patient dataset showing immune remodelling that matches the wider mechanistic story.

NK-cell effects

Preclinical context

NK cells are innate immune cytotoxic lymphocytes that can kill tumour cells without requiring prior antigen sensitisation.

They are suppressed in most cancer patients, partly through mitochondrial dysfunction and partly through immunosuppressive signals in the tumour microenvironment, especially kynurenine-AhR signalling.

Human evidence — prostate-cancer ex vivo study

This is the clearest published human NK-cell dataset for Urolithin A in a cancer setting.

PBMCs from prostate-cancer patients and healthy controls were incubated with Urolithin A at physiologically relevant concentrations.

At 10 µM, Urolithin A increased NK-cell cytotoxic activity against K562 target cells by an average of 23% in prostate-cancer patients.

The mechanism was identified as AhR antagonism.

That matters because kynurenines are elevated in many tumour settings and suppress NK-cell function through AhR engagement.

By blocking that pathway, Urolithin A may help restore NK-cell cytotoxicity.

This is ex vivo evidence, not in vivo clinical-outcome evidence.

So the clearest conclusion is that Urolithin A can improve NK-cell killing capacity in prostate-cancer patient cells under realistic experimental conditions.

It is not yet proof of clinical anti-tumour benefit.

The same study also found lower production of several inflammatory cytokines from prostate-cancer patient PBMCs, including fractalkine, IL-8, and MCP-3, without suppressing cytotoxic function.

That pattern fits the broader idea of immune rebalancing rather than simple stimulation.

AhR antagonism — the immunological significance

The aryl hydrocarbon receptor is a ligand-activated transcription factor with a major role in immune tolerance.

In cancer:

• AhR is overexpressed in multiple tumour types

• AhR supports immune-suppressive signalling and tumour immune evasion

• kynurenines produced by IDO1 and TDO2 are potent AhR agonists

• AhR activation suppresses NK-cell and T-cell function and supports regulatory and M2-like immune states

Urolithin A has been formally identified as a selective human AhR antagonist and described as the first dietary-derived microbiota-produced compound characterised this way.

That makes it unusually important as a postbiotic with direct immune-tolerance relevance.

Reported downstream effects include:

• suppression of AhR-driven gene programmes such as CYP1A1, IL-6, and PTGS2

• blockade of TCDD-equivalent AhR activation

• anti-inflammatory effects that weaken when AhR is knocked down experimentally

This connects Urolithin A's microbiome origin directly to one of the tumour microenvironment's primary immune-suppression mechanisms.

Tumour-associated macrophage reprogramming

Tumour-associated macrophages in many solid tumours adopt a tumour-promoting M2-like phenotype.

Urolithin A appears able to disrupt that pattern through the TFEB-mitophagy axis.

The mechanism is described most fully in the breast-cancer evidence page.

The current model is:

• Urolithin A blocks TFEB sequestration by 14-3-3 protein

• TFEB translocates to the nucleus

• mitophagy is activated in macrophages

• damaged mitochondria are cleared

• NF-κB-driven inflammatory output falls

• IL-6 and TNF-α secretion decreases

• the IL-6/STAT3 autocrine loop that helps sustain tumour-promoting macrophage behaviour is disrupted

This has been validated in co-culture work and supported by in vivo xenograft findings.

It is one of the clearest examples of Urolithin A affecting the immune microenvironment rather than only the tumour cell.

Stromal immune microenvironment — pancreatic cancer

Pancreatic ductal adenocarcinoma is notable for its dense desmoplastic stroma, which physically excludes immune cells and is one of the main reasons checkpoint inhibitors fail.

In a genetically engineered mouse model of pancreatic cancer, Urolithin A reduced stromal fibrosis and improved the conditions for immune infiltration.

Combined Urolithin A plus anti-PD-1 treatment produced:

• enhanced CD4-positive Th1 infiltration

• reinvigorated adaptive T-cell responses

• a statistically significant improvement in overall survival compared with anti-PD-1 alone

This is the most clinically compelling immunosensitisation finding in the Urolithin A literature.

It remains preclinical.

Because pancreatic cancer is so resistant to immunotherapy, the result is especially important.

An NIH-funded research programme is actively extending this work.

The active clinical trial

NCT07161310 is the only registered clinical trial directly studying Urolithin A's effects on the immune systems of cancer patients receiving immune checkpoint inhibitors.

Key details:

• MitoPure 1000 mg/day

• cancer patients on active checkpoint-inhibitor therapy

• primary measures including cytokine profiles, T-cell transcriptional changes, and NK-cell activity

• active trial status

This trial will provide the first prospective in vivo human data on whether the preclinical and ex vivo immune findings translate into measurable immune changes in cancer patients on immunotherapy.

Systemic inflammation

A consistent secondary finding across human Urolithin A trials is reduced circulating inflammatory tone.

Reported findings include reductions in:

• CRP

• IFN-γ

• TNF-α

• IL-1β

• fractalkine

• IL-8

• MCP-3

The exact pattern varies by study and population.

Taken together, the data suggest that Urolithin A can reduce inflammatory burden without simply suppressing useful anti-tumour immune function.

That does not prove anti-cancer benefit.

It does make the compound more relevant in patients carrying a high inflammatory burden.

Important clinical cautions

Additive immune activation with checkpoint inhibitors

Urolithin A activates NK cells, enhances CD8-positive T-cell function, and can reduce tumour-cell PD-L1 expression in some models.

That may complement checkpoint therapy.

It may also increase the risk of additive immune stimulation in settings where immune-related adverse events are already a major clinical issue.

Patients on active checkpoint inhibitors should not add Urolithin A casually.

Healthy-adult data cannot be directly extrapolated to cancer patients

The Nature Aging trial enrolled healthy middle-aged adults.

Cancer patients have heavier immune exhaustion burdens, treatment-related immune disruption, and fundamentally different immune landscapes.

The cancer-patient abstract data is encouraging but still early.

AhR antagonism has complex biology

AhR does not play the same role in every cancer and every immune context.

The current data make Urolithin A's AhR antagonism look favourable in the settings studied so far.

That does not mean every tumour context will behave identically.

Evidence level summary

Bottom line

The immune case for Urolithin A is one of the strongest parts of its oncology profile.

That case now includes:

• a well-developed mitophagy mechanism

• preclinical evidence for stronger T-cell and macrophage function

• human NK-cell data in prostate-cancer patients

• a randomised human immune-phenotyping trial

• early prospective cancer-patient immune-remodelling data

• and an active checkpoint-inhibitor combination study

That is still not enough to call it clinically proven.

It is enough to say that immune modulation is central, not peripheral, to how Urolithin A appears to work.

References

Effect of the mitophagy inducer Urolithin A on age-related immune decline
https://www.nature.com/articles/s43587-025-00996-x

Impact of Urolithin A supplementation, a mitophagy activator, on immune remodeling in cancer patients
https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e14562

Urolithin A increases the natural killer activity of PBMCs in patients with prostate cancer
https://pmc.ncbi.nlm.nih.gov/articles/PMC11754188/

Remodeling of stromal immune microenvironment by Urolithin A leads to enhanced anti-tumour T-cell response and sensitisation to anti-PD-1 immunotherapy in pancreatic cancer
https://pubmed.ncbi.nlm.nih.gov/37448553/

Expansion of T memory stem cells with superior anti-tumour immunity by Urolithin A-induced mitophagy
https://www.sciencedirect.com/science/article/pii/S1074761322005088

Impact of Urolithin A supplementation on immune phenotyping in cancer patients
https://academic.oup.com/jimmunol/article/212/1_Supplement/1532_4882/7996106

Urolithin A is a dietary microbiota-derived human aryl hydrocarbon receptor antagonist
https://pmc.ncbi.nlm.nih.gov/articles/PMC6315438/

Urolithin A inhibits breast cancer progression via activating TFEB-mediated mitophagy in tumour macrophages
https://pmc.ncbi.nlm.nih.gov/articles/PMC11954813/

Clinical trial NCT07161310
https://clinicaltrials.gov/study/NCT07161310

Combining immunotherapy with Urolithin A to improve pancreatic cancer outcomes
https://grantome.com/grant/NIH/R03-CA249401-01